AGILE THERAPEUTICS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Agile Therapeutics Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2014 to Q2 2024.
  • Agile Therapeutics Inc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$11.9M, a 212% decline year-over-year.
  • Agile Therapeutics Inc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$15.9M, a 16.8% increase year-over-year.
  • Agile Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$14.5M, a 43.1% increase from 2022.
  • Agile Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$25.4M, a 64.2% increase from 2021.
  • Agile Therapeutics Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$71.1M, a 37.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$15.9M -$11.9M -$8.06M -212% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$7.79M $1.28M +$6.67M Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-12
Q4 2023 -$14.5M -$4.47M -$539K -13.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$13.9M -$799K +$5.13M +86.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$19.1M -$3.81M +$1.36M +26.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$20.4M -$5.39M +$5M +48.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-12
Q4 2022 -$25.4M -$3.93M +$15.6M +79.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$41M -$5.93M +$10.8M +64.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$51.9M -$5.17M +$12.5M +70.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$64.3M -$10.4M +$6.74M +39.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$71.1M -$19.5M -$1.91M -10.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-28
Q3 2021 -$69.2M -$16.8M -$1.25M -8.04% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$67.9M -$17.6M -$6.81M -62.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$61.1M -$17.1M -$9.25M -117% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$51.9M -$17.6M -$11.6M -193% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$40.3M -$15.5M -$11.1M -250% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-12-30
Q2 2020 -$29.2M -$10.8M -$7.34M -211% Apr 1, 2020 Jun 30, 2020 10-Q/A 2021-12-30
Q1 2020 -$21.8M -$7.88M -$3.21M -68.8% Jan 1, 2020 Mar 31, 2020 10-Q/A 2021-12-30
Q4 2019 -$18.6M -$6.02M -$2.21M -58% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$16.4M -$4.43M -$640K -16.9% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$15.8M -$3.48M +$1.86M +34.8% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$17.6M -$4.67M +$2.16M +31.7% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$19.8M -$3.81M +$2.43M +38.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-20
Q3 2018 -$22.2M -$3.79M +$3.31M +46.6% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-20
Q2 2018 -$25.5M -$5.34M +$2.1M +28.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-20
Q1 2018 -$27.6M -$6.83M +$683K +9.09% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-20
Q4 2017 -$28.3M -$6.24M -$1.04M -20% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$27.3M -$7.1M +$702K +9% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$28M -$7.45M +$972K +11.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$28.9M -$7.52M -$198K -2.71% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$28.7M -$5.2M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 -$7.8M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-12
Q2 2016 -$8.42M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-12
Q1 2016 -$7.32M +$1.22M +14.3% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-12
Q1 2015 -$8.54M -$9.38M -1117% Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-12
Q1 2014 $839K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.